Introducing Empasmile 25: Advancing the Future of Diabetes Care
We are proud to announce the launch of Empasmile 25, an advanced empagliflozin-based therapy developed to transform the management of type 2 diabetes mellitus. With a proven track record in glycemic control and cardiovascular protection, Empasmile 25 empowers healthcare providers and patients to achieve better outcomes with confidence and ease.
Empasmile 25 is a highly selective sodium-glucose co-transporter 2 (SGLT2) inhibitor that works by promoting urinary glucose excretion, thereby lowering blood sugar levels effectively and sustainably. Beyond glycemic control, Empasmile 25 is also clinically proven to offer cardiovascular and renal benefits, making it a comprehensive choice in the modern management of diabetes.
Crafted to the highest standards of pharmaceutical innovation, Empasmile 25 offers:
- Effective and Sustained Glycemic Control
- Reduction in Cardiovascular Risk
- Renal Protection Benefits
- Improved Weight Management and Blood Pressure Reduction
Key Features of Empasmile 25:
- Mechanism of Action: Inhibits SGLT2 in the proximal renal tubules, reducing glucose reabsorption and increasing urinary glucose excretion.
- Indications: Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes; also indicated to reduce the risk of cardiovascular death in patients with type 2 diabetes and established cardiovascular disease.
- Patient-Centric Approach: Once-daily oral administration ensures high compliance and ease of use.
- Manufactured to International Standards: Delivering consistent quality, safety, and therapeutic efficacy.
Empowering Lives, Enabling Smiles
With Empasmile 25, managing diabetes becomes more than controlling numbers — it becomes about improving lives with innovation, trust, and hope.
Now available.
Talk to your healthcare provider about Empasmile today.
